IL4R and Alzheimer disease: Moreover, Guttman-Yassky et al. confirmed that dupilumab, a monoclonal antibody that specifically targets IL-4Rα, thereby blocking the Th17/Th22 pathway, is highly efficacious for controlling skin disease in moderate-to-severe AD patients45.